| Primary | Change From Baseline in the Hamilton Anxiety Scale (HAM-A) Total Score at Week 8 | The HAM-A is an anxiety rating scale consisting of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behavior at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total scores range from 0 to 56 where <17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe. Total scores above 30 are rare, but indicate very severe anxiety. Least Squares (LS) means were from a mixed model for repeated measurements (MMRM) with Baseline-by-week, center, week and week-by-treatment as factors in the analysis. | The Full Analysis Set included all patients who were randomized, received at least 1 dose of study drug, and had at least 1 post-baseline value for assessment of primary efficacy. A mixed model for repeated measurements (MMRM) based on observed cases was used. | Posted | | Least Squares Mean | Standard Error | scores on a scale | | Baseline to Week 8 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Vortioxetine placebo-matching capsules, orally, once daily for up to 8 weeks. | | OG001 | Vortioxetine 5 mg | Vortioxetine 5 mg, encapsulated tablets, orally, once daily for up to 8 weeks. |
| | | Title | Denominators | Categories |
|---|
| | | Title | Measurements |
|---|
| - OG000-10.49± 0.697
- OG001-14.30± 0.695
|
|
| | Group IDs | Group Description | Statistical Method | Statistical Comment | P-Value | P-Value Comment | Parameter Type | Parameter Value | Dispersion Type | Dispersion Value | Confidence Interval Sides | Confidence Interval % | CI Lower Limit | CI Upper Limit | CI Lower Limit Comment | CI Upper Limit Comment | Estimate Comment | Tested Non-Inferiority | Non-Inferiority Type | Non-Inferiority Comment | Other Analysis Description |
|---|
| P-values were tested at the 5% level of significance (ie, statistical significance if P<0.05). To control for multiplicity, a pre-specified sequential testing procedure was applied to compare 5 mg vortioxetine to placebo; as soon as an endpoint was non-significant at 0.05, the testing procedure stopped for all subsequent endpoints. | Mixed model for repeated measurements | P-values were from a MMRM with Baseline-by-week, center, week and week-by-treatment as factors in the analysis. | <0.001 | Pre-specified sequential statistical testing procedure indicates that when p-value <0.05, hierarchical testing continues. | LS Mean Difference | -3.81 | Standard Error of the Mean | 0.981 | 2-Sided | 95 | -5.74 | -1.88 | | | |
|
| Secondary | Change From Baseline in the Hospital Anxiety and Depression (HAD) Anxiety Subscale at Week 8 | The Hospital Anxiety and Depression (HAD) Anxiety sub-scale consists of 7 items that are assessed on a scale from 0 (no anxiety) to 3 (severe feeling of anxiety). The anxiety subscale determines a state of generalized anxiety including anxious mood, restlessness, anxious thoughts and panic attacks. Scores are summed and range from 0 to 21 (maximal severity). LS means were from a MMRM with Baseline-by-week, center, week and week-by-treatment as factors in the analysis. | Full analysis set. A mixed model for repeated measurements (MMRM) based on observed cases was used. | Posted | | Least Squares Mean | Standard Error | scores on a scale | | Baseline to Week 8 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Vortioxetine placebo-matching capsules, orally, once daily for up to 8 weeks. | | OG001 | Vortioxetine 5 mg | Vortioxetine 5 mg, encapsulated tablets, orally, once daily for up to 8 weeks. |
| |
| Secondary | Clinical Global Impression Scale-Global Improvement at Week 8 | The Clinical Global Impression-Global Improvement scale assesses the participant's improvement (or worsening) as assessed by the clinician relative to Baseline on a 7-point scale: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse. LS means were from a MMRM with baseline-by-week, center, week and week-by-treatment as factors in the analysis. | Full analysis set. A mixed model for repeated measurements (MMRM) based on observed cases was used. | Posted | | Least Squares Mean | Standard Error | scores on a scale | | Baseline to Week 8 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Vortioxetine placebo-matching capsules, orally, once daily for up to 8 weeks. | | OG001 | Vortioxetine 5 mg | Vortioxetine 5 mg, encapsulated tablets, orally, once daily for up to 8 weeks. |
| |
| Secondary | Change From Baseline in Sheehan Disability Scale (SDS) Total Score at Week 8 | The Sheehan Disability Scale assesses functional impairment in 3 domains: work/school, social life or leisure activities, and home life or family responsibilities. The participant rates the extent to which each aspect is impaired on a 10-point visual analog scale, from 0 (not at all) to 10 (extremely). The 3 scores are added together to calculate the total score, which ranges from 0 to 30, with higher scores indicating more impairment. LS means were from a MMRM with Baseline-by-week, center, week and week-by-treatment as factors in the analysis. | Full analysis set. A mixed model for repeated measurements (MMRM) based on observed cases was used. | Posted | | Least Squares Mean | Standard Error | scores on a scale | | Baseline to Week 8 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Vortioxetine placebo-matching capsules, orally, once daily for up to 8 weeks. | | OG001 | Vortioxetine 5 mg | Vortioxetine 5 mg, encapsulated tablets, orally, once daily for up to 8 weeks. |
| |
| Secondary | Percentage of Responders in HAM-A Total Score at Week 8 | Response was defined as participants with a ≥ 50% decrease from Baseline in the Hamilton Anxiety Scale (HAM-A) total score. The HAM-A is an anxiety rating scale consisting of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behavior at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total scores range from 0 (symptoms absent) to 56 (maximum severity). | Full analysis set; Last observation carried forward was used. | Posted | | Number | | percentage of participants | | Baseline and Week 8 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Vortioxetine placebo-matching capsules, orally, once daily for up to 8 weeks. | | OG001 | Vortioxetine 5 mg | Vortioxetine 5 mg, encapsulated tablets, orally, once daily for up to 8 weeks. |
| |
| Secondary | Change From Baseline in the Hamilton Anxiety Scale (HAM-A) Total Score at Week 8 in Participants With Baseline HAM-A ≥25 | The HAM-A is an anxiety rating scale consisting of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behavior at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total scores range from 0 to 56 where <17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe. Total scores above 30 are rare, but indicate very severe anxiety. LS means were from a MMRM with Baseline-by-week, center, week and week-by-treatment as factors in the analysis. | Full analysis set patients with a HAM-A Baseline score ≥25. A mixed model for repeated measurements (MMRM) based on observed cases was used. | Posted | | Least Squares Mean | Standard Error | scores on a scale | | Baseline to Week 8 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Vortioxetine placebo-matching capsules, orally, once daily for up to 8 weeks. | | OG001 | Vortioxetine 5 mg | Vortioxetine 5 mg, encapsulated tablets, orally, once daily for up to 8 weeks. |
| |
| Secondary | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Social Functioning Subscore at Week 8 | The Medical Outcomes Study SF-36 is a participant self-rated questionnaire that is a general measure of perceived health status comprising 36 questions, which yields an 8-scale health profile. The social functioning subscale assesses limitations in social activities because of physical or emotional problems. The sub-score scale ranges from 0 (best) - 100 (worst). LS means were from a MMRM with Baseline-by-week, center, week and week-by-treatment as factors in the analysis. | The Full Analysis Set. A mixed model for repeated measurements (MMRM) based on observed cases was used. | Posted | | Least Squares Mean | Standard Error | scores on a scale | | Baseline to Week 8 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Vortioxetine placebo-matching capsules, orally, once daily for up to 8 weeks. | | OG001 | Vortioxetine 5 mg | Vortioxetine 5 mg, encapsulated tablets, orally, once daily for up to 8 weeks. |
| |
| Secondary | Change From Baseline in Hamilton Anxiety Scale (HAM-A) Total Score at Other Weeks Assessed | The HAM-A is an anxiety rating scale consisting of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behavior at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total scores range from 0 to 56 where <17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe. Total scores above 30 are rare, but indicate very severe anxiety. LS means were from a MMRM with Baseline-by-week, center, week and week-by-treatment as factors in the analysis. | The Full Analysis Set. A mixed model for repeated measurements (MMRM) based on observed cases was used; "n" indicates the number of patients included in the analysis at each time point. | Posted | | Least Squares Mean | Standard Error | scores on a scale | | Baseline to Weeks 1, 2, 4 and 6. | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Vortioxetine placebo-matching capsules, orally, once daily for up to 8 weeks. | | OG001 | Vortioxetine 5 mg | Vortioxetine 5 mg, encapsulated tablets, orally, once daily for up to 8 weeks. |
| |
| Secondary | Change From Baseline in the Hospital Anxiety and Depression (HAD) Anxiety Subscale at Other Weeks Assessed | The Hospital Anxiety and Depression (HAD) Anxiety sub-scale consists of 7 items that are assessed on a scale from 0 (no anxiety) to 3 (severe feeling of anxiety). The anxiety subscale determines a state of generalized anxiety including anxious mood, restlessness, anxious thoughts and panic attacks. Scores are summed and range from 0 to 21 (maximal severity). LS means were from a MMRM with Baseline-by-week, center, week and week-by-treatment as factors in the analysis. | The Full Analysis Set. A mixed model for repeated measurements (MMRM) based on observed cases was used; "n" indicates the number of patients included in the analysis at each time point. | Posted | | Least Squares Mean | Standard Error | scores on a scale | | Baseline to Weeks 1 and 4 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Vortioxetine placebo-matching capsules, orally, once daily for up to 8 weeks. | | OG001 | Vortioxetine 5 mg | Vortioxetine 5 mg, encapsulated tablets, orally, once daily for up to 8 weeks. |
| |
| Secondary | Clinical Global Impression Scale-Global Improvement at Other Weeks Assessed | The Clinical Global Impression-Global Improvement scale assesses the participant's improvement (or worsening) as assessed by the clinician relative to Baseline on a 7-point scale: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse. LS means were from a MMRM with Baseline-by-week, center, week and week-by-treatment as factors in the analysis. | Full analysis set. A mixed model for repeated measurements (MMRM) based on observed cases was used; "n" indicates the number of patients included in the analysis at each time point. | Posted | | Least Squares Mean | Standard Error | scores on a scale | | Baseline to Weeks 1, 2, 4 and 6 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Vortioxetine placebo-matching capsules, orally, once daily for up to 8 weeks. | | OG001 | Vortioxetine 5 mg | Vortioxetine 5 mg, encapsulated tablets, orally, once daily for up to 8 weeks. |
| |
| Secondary | Change From Baseline in Sheehan Disability Scale (SDS) Total Score at Other Weeks Assessed | The Sheehan Disability Scale assesses functional impairment in 3 domains: work/school, social life or leisure activities, and home life or family responsibilities. The participant rates the extent to which each aspect is impaired on a 10-point visual analog scale, from 0 (not at all) to 10 (extremely). The 3 scores are added together to calculate the total score, which ranges from 0 to 30, with higher scores indicating more impairment. LS means were from a MMRM with Baseline-by-week, center, week and week-by-treatment as factors in the analysis. | Full analysis set where Baseline data were available. A mixed model for repeated measurements (MMRM) based on observed cases was used. "n" indicates the number of patients included in the analysis at each time point. | Posted | | Least Squares Mean | Standard Error | scores on a scale | | Baseline to Weeks 1, 2 and 4 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Vortioxetine placebo-matching capsules, orally, once daily for up to 8 weeks. | | OG001 | Vortioxetine 5 mg | Vortioxetine 5 mg, encapsulated tablets, orally, once daily for up to 8 weeks. |
| |
| Secondary | Percentage of Responders in HAM-A Total Score at Other Weeks Assessed | Response was defined as participants with a ≥ 50% decrease from Baseline in the Hamilton Anxiety Scale (HAM-A) total score. The HAM-A is an anxiety rating scale consisting of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behavior at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total scores range from 0 (symptoms absent) to 56 (maximum severity). | Full analysis set; Last observation carried forward was used. "n" indicates the number of patients included in the analysis at each time point. | Posted | | Number | | percentage of participants | | Baseline and Weeks 1, 2, 4 and 6 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Vortioxetine placebo-matching capsules, orally, once daily for up to 8 weeks. | | OG001 | Vortioxetine 5 mg | Vortioxetine 5 mg, encapsulated tablets, orally, once daily for up to 8 weeks. |
| |
| Secondary | Change From Baseline in the Hamilton Anxiety Scale (HAM-A) Total Score at Other Weeks Assessed in Participants With Baseline HAM-A ≥25 | The HAM-A is an anxiety rating scale consisting of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behavior at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total scores range from 0 to 56 where <17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe. Total scores above 30 are rare, but indicate very severe anxiety. LS means were from a MMRM with Baseline-by-week, center, week and week-by-treatment as factors in the analysis. | Full analysis set patients with a HAM-A Baseline score ≥25. A mixed model for repeated measurements (MMRM) based on observed cases was used; "n" indicates the number of patients included in the analysis at each time point. | Posted | | Least Squares Mean | Standard Error | scores on a scale | | Baseline to Weeks 1, 2, 4 and 6 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Vortioxetine placebo-matching capsules, orally, once daily for up to 8 weeks. | | OG001 | Vortioxetine 5 mg | Vortioxetine 5 mg, encapsulated tablets, orally, once daily for up to 8 weeks. |
| |
| Secondary | Percentage of Participants in HAM-A Remission at Each Week Assessed | Remission is defined as a Hamilton Anxiety Scale (HAM-A) total score ≤ 7. The HAM-A is an anxiety rating scale consisting of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behavior at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total scores range from 0 (symptoms absent) to 56 (maximum severity). | Full analysis set; Last observation carried forward was used. "n" indicates the number of patients included in the analysis at each time point. | Posted | | Number | | percentage of participants | | Weeks 1, 2, 4, 6 and 8 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Vortioxetine placebo-matching capsules, orally, once daily for up to 8 weeks. | | OG001 | Vortioxetine 5 mg | Vortioxetine 5 mg, encapsulated tablets, orally, once daily for up to 8 weeks. |
| |
| Secondary | Change From Baseline in Clinical Global Impression Scale-Severity of Illness at Each Week Assessed | The Clinical Global Impression-Severity scale (CGI-S) is a 7-point scale that requires the clinician to rate the severity of the patient's illness at the time of assessment, relative to the clinician's past experience with patients who have the same diagnosis. Considering total clinical experience, a patient is assessed on severity of mental illness on the following scale: 1, normal, not at all ill; 2, borderline mentally ill; 3, mildly ill; 4, moderately ill; 5, markedly ill; 6, severely ill; or 7, extremely ill. LS means were from a MMRM with Baseline-by-week, center, week and week-by-treatment as factors in the analysis. | Full analysis set. A mixed model for repeated measurements (MMRM) based on observed cases was used; "n" indicates the number of patients included in the analysis at each time point. | Posted | | Least Squares Mean | Standard Error | scores on a scale | | Baseline to Weeks 1, 2, 4, 6 and 8 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Vortioxetine placebo-matching capsules, orally, once daily for up to 8 weeks. | | OG001 | Vortioxetine 5 mg | Vortioxetine 5 mg, encapsulated tablets, orally, once daily for up to 8 weeks. |
| |
| Secondary | Change From Baseline in the Hospital Anxiety and Depression (HAD) Depression Subscale at Each Week Assessed | The HAD-Depression subscale is completed by the participant and measures depression, focusing on the state of lost interest and diminished pleasure response. The subscale is made up of 7 items that are assessed on a scale from 0 (no depression) to 3 (severe feeling of depression). Participants are required to indicate the response which most accurately reflects the way they have felt over the last few days. The item scores are summed and the total subscore ranges from 0 to 21 (maximal severity). LS means were from a MMRM with Baseline-by-week, center, week and week-by-treatment as factors in the analysis. | The Full Analysis Set. A mixed model for repeated measurements (MMRM) based on observed cases was used; "n" indicates the number of patients included in the analysis at each time point. | Posted | | Least Squares Mean | Standard Error | scores on a scale | | Baseline to Weeks 1, 4 and 8 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Vortioxetine placebo-matching capsules, orally, once daily for up to 8 weeks. | | OG001 | Vortioxetine 5 mg | Vortioxetine 5 mg, encapsulated tablets, orally, once daily for up to 8 weeks. |
| |
| Secondary | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Social Functioning Subscore at Other Weeks Assessed | The Medical Outcomes Study SF-36 is a participant self-rated questionnaire that is a general measure of perceived health status comprising 36 questions, which yields an 8-scale health profile. The social functioning subscale assesses limitations in social activities because of physical or emotional problems. The sub-score scale ranges from 0 (best) - 100 (worst). LS means were from a MMRM with Baseline-by-week, center, week and week-by-treatment as factors in the analysis. | The Full Analysis Set with available data at Baseline. A mixed model for repeated measurements (MMRM) based on observed cases was used; "n" indicates the number of patients included in the analysis at each time point. | Posted | | Least Squares Mean | Standard Error | scores on a scale | | Baseline to Weeks 2 and 4 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Vortioxetine placebo-matching capsules, orally, once daily for up to 8 weeks. | | OG001 | Vortioxetine 5 mg | Vortioxetine 5 mg, encapsulated tablets, orally, once daily for up to 8 weeks. |
| |
| Secondary | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Physical Functioning Subscore at Each Week Assessed | The Medical Outcomes Study SF-36 is a participant self-rated questionnaire that is a general measure of perceived health status comprising 36 questions, which yields an 8-scale health profile. The physical functioning subscale assesses limitations in physical activities because of health problems. The sub-score scale ranges from 0 (best) - 100 (worst). LS means were from a MMRM with Baseline-by-week, center, week and week-by-treatment as factors in the analysis. | The Full Analysis Set with available data at Baseline. A mixed model for repeated measurements (MMRM) based on observed cases was used; "n" indicates the number of patients included in the analysis at each time point. | Posted | | Least Squares Mean | Standard Error | scores on a scale | | Baseline to Weeks 2, 4 and 8 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Vortioxetine placebo-matching capsules, orally, once daily for up to 8 weeks. | | OG001 | Vortioxetine 5 mg | Vortioxetine 5 mg, encapsulated tablets, orally, once daily for up to 8 weeks. |
| |
| Secondary | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Role-Physical Subscore at Each Week Assessed | The Medical Outcomes Study SF-36 is a participant self-rated questionnaire that is a general measure of perceived health status comprising 36 questions, which yields an 8-scale health profile. The role-physical subscale assesses limitations in usual role activities because of physical health problems. The sub-score scale ranges from 0 (best) - 100 (worst). LS means were from a MMRM with Baseline-by-week, center, week and week-by-treatment as factors in the analysis. | The Full Analysis Set with available data at Baseline. A mixed model for repeated measurements (MMRM) based on observed cases was used; "n" indicates the number of patients included in the analysis at each time point. | Posted | | Least Squares Mean | Standard Error | scores on a scale | | Baseline to Weeks 2, 4 and 8 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Vortioxetine placebo-matching capsules, orally, once daily for up to 8 weeks. | | OG001 | Vortioxetine 5 mg | Vortioxetine 5 mg, encapsulated tablets, orally, once daily for up to 8 weeks. |
| |
| Secondary | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Bodily Pain Subscore at Each Week Assessed | The Medical Outcomes Study SF-36 is a participant self-rated questionnaire that is a general measure of perceived health status comprising 36 questions, which yields an 8-scale health profile. The bodily pain sub-score scale ranges from 0 (best) - 100 (worst). LS means were from a MMRM with Baseline-by-week, center, week and week-by-treatment as factors in the analysis. | The Full Analysis Set with available data at Baseline. A mixed model for repeated measurements (MMRM) based on observed cases was used; "n" indicates the number of patients included in the analysis at each time point. | Posted | | Least Squares Mean | Standard Error | scores on a scale | | Baseline to Weeks 2, 4 and 8 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Vortioxetine placebo-matching capsules, orally, once daily for up to 8 weeks. | | OG001 | Vortioxetine 5 mg | Vortioxetine 5 mg, encapsulated tablets, orally, once daily for up to 8 weeks. |
| |
| Secondary | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) General Health Subscore at Each Week Assessed | The Medical Outcomes Study SF-36 is a participant self-rated questionnaire that is a general measure of perceived health status comprising 36 questions, which yields an 8-scale health profile. The general health sub-score scale ranges from 0 (best) - 100 (worst). LS means were from a MMRM with Baseline-by-week, center, week and week-by-treatment as factors in the analysis. | The Full Analysis Set with available data at Baseline. A mixed model for repeated measurements (MMRM) based on observed cases was used; "n" indicates the number of patients included in the analysis at each time point. | Posted | | Least Squares Mean | Standard Error | scores on a scale | | Baseline to Weeks 2, 4 and 8 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Vortioxetine placebo-matching capsules, orally, once daily for up to 8 weeks. | | OG001 | Vortioxetine 5 mg | Vortioxetine 5 mg, encapsulated tablets, orally, once daily for up to 8 weeks. |
| |
| Secondary | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Vitality Subscore at Each Week Assessed | The Medical Outcomes Study SF-36 is a participant self-rated questionnaire that is a general measure of perceived health status comprising 36 questions, which yields an 8-scale health profile. The vitality sub-score assesses energy and fatigue, and ranges from 0 (best) - 100 (worst). LS means were from a MMRM with Baseline-by-week, center, week and week-by-treatment as factors in the analysis. | The Full Analysis Set with available data at Baseline. A mixed model for repeated measurements (MMRM) based on observed cases was used; "n" indicates the number of patients included in the analysis at each time point. | Posted | | Least Squares Mean | Standard Error | scores on a scale | | Baseline to Weeks 2, 4 and 8 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Vortioxetine placebo-matching capsules, orally, once daily for up to 8 weeks. | | OG001 | Vortioxetine 5 mg | Vortioxetine 5 mg, encapsulated tablets, orally, once daily for up to 8 weeks. |
| |
| Secondary | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Role-Emotional Subscore at Each Week Assessed | The Medical Outcomes Study SF-36 is a participant self-rated questionnaire that is a general measure of perceived health status comprising 36 questions, which yields an 8-scale health profile. The role-emotional subscale assesses limitations in usual role activities because of emotional problems. The sub-score scale ranges from 0 (best) - 100 (worst). LS means were from a MMRM with Baseline-by-week, center, week and week-by-treatment as factors in the analysis. | The Full Analysis Set with available data at Baseline. A mixed model for repeated measurements (MMRM) based on observed cases was used; "n" indicates the number of patients included in the analysis at each time point. | Posted | | Least Squares Mean | Standard Error | scores on a scale | | Baseline to Weeks 2, 4 and 8 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Vortioxetine placebo-matching capsules, orally, once daily for up to 8 weeks. | | OG001 | Vortioxetine 5 mg | Vortioxetine 5 mg, encapsulated tablets, orally, once daily for up to 8 weeks. |
| |
| Secondary | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Mental Health Subscore at Each Week Assessed | The Medical Outcomes Study SF-36 is a participant self-rated questionnaire that is a general measure of perceived health status comprising 36 questions, which yields an 8-scale health profile. The mental health sub-score assesses general mental health (psychological distress and well-being) and ranges from 0 (best) - 100 (worst). LS means were from a MMRM with Baseline-by-week, center, week and week-by-treatment as factors in the analysis. | The Full Analysis Set with available data at Baseline. A mixed model for repeated measurements (MMRM) based on observed cases was used; "n" indicates the number of patients included in the analysis at each time point. | Posted | | Least Squares Mean | Standard Error | scores on a scale | | Baseline to Weeks 2, 4 and 8 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Vortioxetine placebo-matching capsules, orally, once daily for up to 8 weeks. | | OG001 | Vortioxetine 5 mg | Vortioxetine 5 mg, encapsulated tablets, orally, once daily for up to 8 weeks. |
| |
| Secondary | Health Care Resource Utilization as Assessed by the Health Economic Assessment Questionnaire | Healthcare resource utilization was assessed by the Health Economic Assessment (HEA) questionnaire, which monitors the participants absenteeism from work, as well as resource use such as visits to a general practitioner, outpatient and inpatient services, hospitalization, medications, and other relevant services over the past 8 weeks. | | Posted | | Number | | participants | | Baseline and Week 8 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Vortioxetine placebo-matching capsules, orally, once daily for up to 8 weeks. | | OG001 | Vortioxetine 5 mg | Vortioxetine 5 mg, encapsulated tablets, orally, once daily for up to 8 weeks. |
| |